ACRS
Aclaris Therapeutics Inc
NASDAQ: ACRS · HEALTHCARE · BIOTECHNOLOGY
$4.47
+5.92% today
Updated 2026-04-29
Market cap
$624.30M
P/E ratio
—
P/S ratio
79.77x
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$1 – $5
Volume
2.0M
Aclaris Therapeutics Inc (ACRS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-4.92M | $-7.64M | $-20.37M | $-34.60M | $-54.66M | $-100.81M | $-96.44M | $-38.63M | $-52.13M | $-67.57M | $-78.33M | $-20.07M | $-47.11M |
| Capital expenditures | $0.00 | $417000.00 | $507000.00 | $232000.00 | $1.24M | $1.36M | $1.61M | $453000.00 | $308000.00 | $605000.00 | $1.31M | $121000.00 | $111000.00 |
| Depreciation | $11000.00 | $12000.00 | $90000.00 | $120000.00 | $402000.00 | $1.88M | $1.59M | $1.32M | $923000.00 | $797000.00 | $863000.00 | $807000.00 | — |
| Stock-based comp | — | $27000.00 | $891000.00 | $6.10M | $14.43M | $20.05M | $16.18M | $11.21M | $14.06M | $15.04M | $20.54M | $10.86M | $12.38M |
| Free cash flow | $-4.92M | $-8.05M | $-20.88M | $-34.84M | $-55.90M | $-102.17M | $-98.06M | $-39.09M | $-52.44M | $-68.17M | $-79.63M | $-20.20M | $-47.22M |
| Investing cash flow | $-4.54M | $-1.78M | $-76.95M | $-61.90M | $-55.69M | $9.37M | $105.68M | $6.39M | $-167.63M | $12.63M | $46.22M | $-69.77M | — |
| Financing cash flow | — | $10.58M | $96.41M | $116.83M | $100.39M | $128.26M | $-30.32M | $18.37M | $225.05M | $72.87M | $26.71M | $74.54M | — |
| Dividends paid | — | — | $0.00 | $0.00 | $0.00 | — | — | $7.74M | $3.12M | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $-906000.00 | $20.32M | $-9.97M | $36.82M | $-21.08M | $-13.87M | $5.29M | $17.93M | — | — | — |